Pancragen Peptide

$65.00

✓ Third-party tested by certified labs

✓ Published certificates of analysis

✓ ≥98.5% purity standard

Category: Bioregulators

Description
Reviews (0)

Pancragen Peptide Description

Pancragen is a tetrapeptide bioregulator composed of the amino acid sequence Lys-Glu-Asp-Trp (KEDW). This laboratory-grade peptide demonstrates significant biological activity in experimental settings, particularly in pancreatic cell culture studies.

Research indicates that Pancragen exhibits notable effects on pancreatic function and glucose metabolism at nanomolar concentrations. The pancreas peptide has been shown to help normalize insulin production and improve pancreatic beta cell regeneration in experimental models, suggesting potential applications in metabolic research.

Pancragen’s mechanism of action appears to involve modulation of gene expression in pancreatic tissues, potentially activating regenerative pathways that support cellular rejuvenation. The peptide demonstrates tissue-specific affinity with minimal off-target effects in laboratory investigations.

This specialized bioregulatoris a valuable research tool for laboratories studying pancreatic function, insulin signaling pathways, and age-related changes in glucose metabolism. Pancragen offers researchers a well-characterized compound for investigating pancreatic cellular resilience and metabolic regulation.

Container:: Glass Vial
Weight:: 20mg
Sequence:: Lys-Glu-Asp-Trp (KEDW)
Molecular Formula:: C₂₆H₃₆N₆O₉
Molecular Weight:: 576.25 g/mol
PubChem CID:: 68452887
Synonyms:: SCHEMBL5491754
IUPAC Name:: (4S)-5-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-1-oxopropan-2-yl]amino]-4-[[(2S)-2,6-diaminohexanoyl]amino]-5-oxopentanoic acid
Storage:: Store in lyophilized form at or below -20°C
Quality Verification:: Third-party tested by certified laboratory
Application:: In vitro research applications only (RUO)

At Limitless Biotech, we provide comprehensive Certificates of Analysis (COAs) for all of our research-only peptides to ensure transparency, purity, and quality in every batch. Each COA includes detailed analytical data that allows researchers to verify identity, concentration, and integrity, supporting reliable and reproducible scientific work. Our commitment to rigorous testing helps researchers move forward with confidence in the materials they use.

Lyophilized Pancragen #1251 Endotoxin COALyophilized Pancragen #1251 Sterility COALyophilized Pancragen #1251 Purity COA

Research

Pancragen has been studied for its potential to restore function of the pancreas in the context of aging and type 2 diabetes. Research has focused on its effects in animal models, examining both endocrine regulation and cellular differentiation in the pancreas.

Mechanisms of Action

In human embryonic pancreatic cell cultures, pancragen specifically stimulated the expression of differentiation factors (CXCL12, Hoxa3), especially in aged cells. This tissue-specific stimulation was more pronounced in older cultures, indicating a possible geroprotective mechanism.^[1]

Effects on Pancreatic Endocrine Function

In older animals, pancragen administration led to decreased basal insulin and C-peptide levels, increased glucose disappearance rates, and normalization of glucose, insulin, and C-peptide responses after glucose administration. These effects partially persisted for three weeks after stopping treatment.^[2] Pancragen was effective in restoring age-related endocrine dysfunctions of the pancreas, suggesting its promise as a therapeutic agent for age-associated glucose intolerance and type 2 diabetes.^[2]

Effectiveness in Diabetes Models

In elderly patients with type 2 diabetes, pancragen administration led to significant reductions in fasting glucose, improved glucose tolerance, and decreased insulin resistance. These benefits were not observed in patients who did not receive pancragen, suggesting a specific therapeutic effect.^[3] In diabetic rats, pancragen normalized the adhesion of mesenteric capillary endothelium, suggesting protective effects on vascular function during early diabetes, though it did not affect capillary permeability.^[4] Oral pancragen produced a significant hypoglycemic effect during treatment, supporting its potential for blood glucose regulation in diabetes. The peptide also demonstrated homeostatic effects in diabetic conditions, further supporting its research potential.^[4]

References

Khavinson, V., Linkova, N., Polyakova, V., Kheifets, O., Tarnovskaya, S., & Kvetnoy, I. (2012). Peptides Tissue-Specifically Stimulate Cell Differentiation during Their Aging. Bulletin of Experimental Biology and Medicine, 153, 148-151. https://doi.org/10.1007/s10517-012-1664-1.
Goncharova, N., Ivanova, L., Oganian, T., Vengerin, A., & Khavinson, V. (2014). [Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys].. Advances in gerontology = Uspekhi gerontologii, 27 4, 662-7.
Korkushko, O., Khavinson, V., Shatilo, V., Antonyk-Sheglova, I., & Bondarenko, E. (2011). Prospects of Using Pancragen for Correction of Metabolic Disorders in Elderly People. Bulletin of Experimental Biology and Medicine, 151, 454-456. https://doi.org/10.1007/s10517-011-1354-4.
Khavinson, V., Gavrisheva, N., Malinin, V., Chefu, S., & Trofimov, E. (2007). Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus. Bulletin of Experimental Biology and Medicine, 144, 559-562. https://doi.org/10.1007/s10517-007-0377-3.